Caplight Directory>Companies>Verdiva Bio-preview>Verdivabio


Verdiva Bio

Verdiva Bio

Private
GuildfordHealthcare & Life Scienceshttps://verdivabio.com/

Last Round

Series A

1/9/2025

Total Funding Raised

$411M

Momentum Score

100 /100

Company Overview

Verdiva Bio is a biopharmaceutical company that develops next-generation therapies designed to help people living with obesity, cardiometabolic disorders, and related complications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

obesity treatmentoral GLP-1weight loss drugsGLP-1 receptor agonistGLP-1 drugsweight loss pillamylin agonistcardiometabolic therapiesclinical-stage biotechdrug in-licensingweight loss maintenanceoral peptide

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Verdiva Bio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Verdiva Bio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series A1/9/2025
View all Funding Rounds

Key People

Founding team and executive leadership

Tapan Maniar

Chief Business Officer Co-Founder

Founding Team

Khurem F.

Chief Executive Officer

Executive Team

Ashley Taylor

Chief Technology Officer

Executive Team

Verdiva Bio Investors

Notable investors and investment history

InvestorRounds
Forbion Capital PartnersSeries A
RA Capital ManagementSeries A
LYFE CapitalSeries A
OrbiMedSeries A
Logos CapitalSeries A
Lilly Asia VenturesSeries A
General AtlanticSeries A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 25, 2026

    Grew 25% QoQ, from 59 to 74 employees.

  • Apr 19, 2026

    Monthly visitors increased 448% MoM to 5.4K.

View all signals

Verdiva Bio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Verdiva Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Verdiva Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersGuildford
Employee Range74
Year Founded2024
Last Funding1/9/2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


DisclaimerAll investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.